Comparative evaluation of oral chondroprotectors effectiveness in patients with low back pain

Shavlovskaya O.A.; Romanov I.D.; Bokova I.A.

doi:https://doi.org/10.17116/jnevro202512507198

Shavlovskaya O.A.

International university of restorative medicine

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Romanov I.D.

International university of restorative medicine

ORCID: 0000-0002-0756-7961

Bokova I.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-1640-1605

Comparative evaluation of oral chondroprotectors effectiveness in patients with low back pain

Authors:

Shavlovskaya O.A., Romanov I.D., Bokova I.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7): 98‑103

DOI: 10.17116/jnevro202512507198

Read: 752 times

Contact the author

Table of contents

To cite this article:

Shavlovskaya OA, Romanov ID, Bokova IA. Comparative evaluation of oral chondroprotectors effectiveness in patients with low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7):98‑103. (In Russ.)
https://doi.org/10.17116/jnevro202512507198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

OBJECTIVE

To evaluate the effectiveness of the three-component pharmaconutrient Chondroguard TRIO — chondroitin sulfate (CS), glucosamine sulfate (GS) and undenatured type II collagen (UC-II) in terms of its effect on the severity of pain syndrome, compared to the two-component chondroprotectors (CP) drugs Artra (CS+glucozamine hydrochloride (GG), Teraflex (CS+GG), and the single-component CP Dona (GS).

MATERIAL AND METHODS

The outpatient records (o/r) of 120 patients (age 58.5±6.2 years) who received CP in polyclinic conditions at their place of residence in the period from September 2024 to May 2025. The patients were divided into 4 groups depending on the drug they received. The o/r on the dynamics of the severity of the pain syndrome and the functional status of the patient were evaluated. Evaluation scales were used: the 10-point visual analog scale (VAS) and the Oswestry Disability Index (ODI).

RESULTS

The dynamics of the indicators demonstrated the effectiveness of the three-component pharmaconutraceutical HondroguardTRIO over the two-component CP Artra and Teraflex, and the single-component CP Dona: a statistically significant decrease in pain syndrome values was obtained. There were no side effects in the Chondroguard TRIO group.

CONCLUSION

The new oral CP Chondroguard TRIO has obvious advantages in composition over popular oral two- and mono-component CPs, which allows us to consider this pharnaconeutic as a potentially new opportunity for chondroprotective support of OA and LBP patients.

Keywords:

lower back pain

osteoarthritis

chondroprotector

glucosamine sulfate

chondroitin sulfate

undenatured type II collagen

pharmaconutraceutical

Chondroguard TRIO

Authors:

Shavlovskaya O.A.

International university of restorative medicine

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Romanov I.D.

International university of restorative medicine

ORCID: 0000-0002-0756-7961

Bokova I.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-1640-1605

Received:

20.06.2025

Accepted:

24.06.2025

Close metadata

References:

Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. https://doi.org/10.1016/j.semarthrit.2019.04.008
Shavlovskaya OA. SYSADOA place in degenerative-dystrophic joints diseases treatment of neurological practice from the standpoint of evidence-based medicine. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(3):30-37. (In Russ.). https://doi.org/10.17116/jnevro202212203138
Shavlovskaya OA, Gromova OA, Torshin IYu, Romanov ID. From misconceptions to reasonable osteoarthritis patients therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(2):317-330. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.183
Shavlovskaya OA. Comparative Analysis of Drugs with Chondroprotective Effect: a Review. Comorbidity Neurology. 2025;2(1):49-55. (In Russ.). https://doi.org/10.62505/3034-185x-2025-2-1-49-55
Danilov AlB, Lila AM, Majidova YoN, et al. New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):134-146. (In Russ.). https://doi.org/10.14412/2074-2711-2023-2-134-146
Alekseeva LI, Barulin AE, Bakhtadze MA, et al. Disease-modifying therapy and adjuvant support in complex therapy of chronic non-specific low back pain. Resolution of the Multidisciplinary Board of Experts. Russian Journal of Pain. 2024;22(3):108-116. (In Russ.). https://doi.org/10.17116/pain202422031108
Chen CS, Wen L, Yang F, et al. Effects of dietary supplements on patients with osteoarthritis: A systematic review and network meta-analysis. J Integr Med. 2025:S2095-4964(25)00053-6. https://doi.org/10.1016/j.joim.2025.04.008
Schön C, Knaub K, Alt W, et al. UC-II undenatured type II collagen for knee joint flexibility: a multicenter, randomized, double-blind, placebo-controlled clinical study. J Integr Complement Med. 2022;28(6):540-548. https://doi.org/10.1089/jicm.2021.0365
Kumar P, Bansal P, Rajnish RK, et al. Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis. Am J Transl Res. 2023;15(9):5545-5555.
Gupta A, Maffulli N. Undenatured type II collagen for knee osteoarthritis. Ann Med. 2025;57(1):2493306. https://doi.org/10.1080/07853890.2025.2493306
Shavlovskaya OA, Yukhnovskaya YuD, Romanov ID, Bokova IA. harmaconutraceutical Chondroguard®TRIO — chondroprotector with immunomodulatory activity. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):105-111. (In Russ.). https://doi.org/10.14412/2074-2711-2023-4-105-111
Gromova OA, Torshin IYu, Lila AM, Shavlovskaya OA. On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases. Modern Rheumatology Journal. 2022;16(4):111-116. (In Russ.). https://doi.org/10.14412/1996-7012-2022-4-111-116
Shavlovskaya OA, Sarvilina IV, Gromova OA, et al. Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):87-95. (In Russ.). https://doi.org/10.14412/2074-2711-2022-4-87-95
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14. https://doi.org/10.1186/s12937-016-0130-8
Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101. https://doi.org/10.5152/eurasianjmed.2015.15030
Lugo JP, Saiyed ZM, Lau FC, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013;10(1):48. https://doi.org/10.1186/1550-2783-10-48.
García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, et al. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019;43(3):531-538. https://doi.org/10.1007/s00264-018-4211-5
Shiojima Y, Takahashi R, Maruyama K, et al. Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo controlled, parallel-group study. J Am Nutr Assoc. 2023;42(3):224-241. https://doi.org/10.1080/07315724.2021.2024466
Gromova OA, Torshin IYu, Lila AM. Molecular Mechanisms of Action of Undenatured Type II Collagen: Experimental and Clinical Evidence. Modern Rheumatology Journal. 2022;16(5):108-113. (In Russ.). https://doi.org/10.14412/1996-7012-2022-5-108-113
Alekseeva LI, Kashevarova NG, Taskina EA, et al. Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Terapevticheskii Arkhiv (Ter. Arkh.). 2025;97(1):54-64. (In Russ.). https://doi.org/10.26442/00403660.2025.01.203145
Mayko OY, Averyanov VN. Clinical efficacy of combined therapy with chondroitin sulfate and glucosamine hydrochloride in patients with osteoarthritis in outpatient settings. Orenburg Medical Bulletin. 2020;3(31):22-27. (In Russ.).
Lila AM, Alekseeva LI, Telyshev KA, et al. The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study. Modern Rheumatology Journal. 2020;14(3):71-78. (In Russ.). https://doi.org/10.14412/1996-7012-2020-3-71-78
Averkiyeva YuV, Raskina TA, Shafiyeva IA, et al. Evaluation of the Combination Therapy Effectiveness with Glucosamine Crystalline Sulfate (DONA) in Patients with Knee Osteoarthritis. Effective Pharmacotherapy. 2019;15(8):10-16. (In Russ.).
Lapshina SA, Afanasyeva MA, Sukhorukova EV, et al. Comparative efficacy of the drug Chondroxide® maximum (cream for external use) and the injectable form of glucosamine sulfate (Dona) in patients with gonarthrosis. Consilium Medicum. 2014;16(2):120-124. (In Russ.).